1. Capacity expansion and upgradation of manufacturing facilities;
2. Establishment of a new R&D Centre;
3. Repayment / prepayment of certain outstanding borrowings;
4. Working capital requirements;
5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and
6. General corporate purposes
...
business of (i) Branded Generic Formulations and (ii) Contract Development and Manufacturing Organisation (“CDMO”) products and services for the domestic and international markets. Our Company’s portfolio includes formulation products across various therapeutic areas like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. In the injectables segment, we have capabilities in sterile manufacturing for critical care and penicillin-based therapies, offering delivery systems that include dry powder injections, pre-filled syringes, ampoules, and vials.We manufacture and sell Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market. We started our export business in Fiscal 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. We export our products to the Regulated and Semi-Regulated Markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors. Our Company’s CDMO business includes comprehensive solutions on product development, validation batches, stability studies, dossier compilation, international regulatory filings and commercial manufacturing. We believe that our R&D expertise and regulatory compliance capabilities positions us as a preferred CDMO partner for our customers in the Regulated and Semi-Regulated Markets. Our Company, through its wholly owned Singapore subsidiary, Sai Parenterals Pte. Limited, has entered into a Share Purchase Agreement dated September 23, 2025 with Noumed Life Sciences Limited (UK), Mark Thulborne, and Jo-maree Delac to acquire a 74.60% majority and controlling stake in Noumed, including an equity infusion of AUD 4.00 million as a primary in Noumed Pharmaceuticals Pte Ltd, Australia. Noumed Pharmaceuticals Pty Limited (“Noumed”), an Australia-based pharmaceutical company in the business of Intellectual Property (IP) dossier-led commercialisation, integrated supply chain management with long-standing partnerships with retail pharmacy networks in Australia. For further details, please see “Objects of the Offer – Investment in wholly owned subsidiary, Sai Parenterals Pte Limited Read More
Posted on Jan 22nd
Currency futures for January expiry trade stronger with 1.31% increase in OI
Posted on Jan 22nd
Zydus Lifesciences informs about press release
Posted on Jan 22nd
India to become world's third-largest economy over next few years: Ashwini Vaishnaw
Posted on Jan 21st
Hannah Joseph Hospital coming with IPO to raise Rs 42 crore
The issue size of Sai Parenteral's Ltd. IPO is ₹0.00 - 0.00 crore.
The Sai Parenteral's Ltd. IPO opens for subscription on and closes on .
The price range of Sai Parenteral's Ltd. IPO is ₹0.00 to ₹0.00.
The lot size of Sai Parenteral's Ltd. IPO is shares.
The registrar of Sai Parenteral's Ltd. IPO is Bigshare Services Pvt Ltd .
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.